SWISS MEDTECH COMPANY HOCOMA PARTNERS WITH XLAB
3rd February 2015
Volketswil near Zurich, Switzerland, February 03, 2015. Hocoma, the global market leader for the development, manufacturing and marketing of robotic and sensor based devices for functional movement therapy, has announced its partnership with the Slovenian software company XLAB. The pilot phase already started in summer 2014, and a team of dedicated XLAB employees is now fully operational and supporting Hocoma. The strategic decision for XLAB as Hocoma’s flexible long-term software development partner is a valuable investment in the future.
Hocoma was set up in 2000, as a spin-off of the Swiss University Hospital Balgrist. The company currently employs more than 170 people at its headquarters in Volketswil near Zurich (Switzerland) and at its subsidiaries in the USA, Singapore and Slovenia. Hocoma is the global market leader for the development, manufacturing and marketing of robotic and sensorbased devices for functional movement therapy. Therapy solutions support the treatment of neurological patients with movement disorders caused by stroke, spinal cord injury, traumatic brain injury, multiple sclerosis, cerebral palsy or other neurological diseases and injuries as well low back pain patients. The product range features devices for intensive gait therapy (Lokomat®), functional therapy of the upper extremities (Armeo®), patient mobilization in early rehabilitation programs (Erigo®) as well as functional movement therapy within low back pain treatment (Valedo®) at home and at the clinic. Hocoma products are applied successfully in clinics and research institutes worldwide. The medical technology company has received many technology and entrepreneur awards, amongst others the “Swiss Technology Award” and the “Ernst&Young Entrepreneur of the Year” award. Hocoma generated a turnover of more than 30 million CHF in 2013. Dr. Gery Colombo is the CEO of Hocoma AG.
All Hocoma products are medical devices and must be used in strict adherence to the User Manual; failure to do so may result in serious personal injury. It is strongly recommended that you regularly consult Hocoma’s website (www.hocoma.com/legalnotes) for the latest available information. Please contact Hocoma in case of any questions.
Use only under the supervision of qualified medical personnel. However, certain Hocoma products are marketed for home use and must be strictly used according to the recommendations of your medical care provider who is knowledgeable about your specific needs. Consult the User Manual and Hocoma’s website (www.hocoma.com/legalnotes) for appropriate product designation. Failure to obtain and follow the recommendations of your medical care provider may result in serious personal injury.
This information provides details about medical products which may not be available in all countries and may not have received approval or market clearance by all governmental regulatory bodies throughout the world. Nothing herein should be construed as a solicitation or promotion of any product or of an indication of any specific use for any product which is not authorized by the laws and regulations of the country where the reader of this information resides.